Zealand Pharma | pharmaphorum

Skip to main content

Friday 8 December 2023

twitter linkedin facebook rss

User account menu

Sign up

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

Zealand Pharma

News

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is

News

Boehringer shows its hand in obesity

Boehringer shows its hand in obesity

Boehringer Ingelheim and partner Zealand Pharma have reported new clinical data in obesity for their dual glucagon/GLP1 agonist BI 456906, setting up a possible challenge

News

zealand pharma

Positive phase 3 results for Zealand Pharma's glepaglutide

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the

News

Alexion

Alexion signs R&D deals with two Nordic biotechs

Alexion has signed a deal with two Nordic biotechs to bolster its pipeline of potential rare disease drugs.

Editor's Picks

AbbVie agrees $10.1bn deal to buy ImmunoGen

UK Biobank releases largest-ever genome sequencing dataset

EVERSANA brings GenAI to medical content approvals

Experts allay fears over pneumonia outbreak in China

Could high HDL-cholesterol raise dementia risk?

News

Vertex Pharmaceutical's Boston headquarters

FDA clears two sickle-cell gene therapies, including CRISPR ...

The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.

on demand

R&D

Revolutionising research: Inside the NCVR evolution in the UK

Sponsored

Revolutionising research: Inside the NCVR evolution in the U...

On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2023, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – a Healthware Group company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2023, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – a Healthware Group company